Back to News
Market Impact: 0.45
Revolution Medicines' Daraxonrasib Secures FDA Breakthrough Designation In Pancreatic Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Revolution Medicines received FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib), its RAS(ON) multi-selective cancer therapy. The designation can expedite development and regulatory review, improving the drug's path toward commercialization and representing a positive catalyst for RVMD.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
RVMD0.82
More News
- Hong Kong telecom company agrees to halt U.S. operations under pressure
- How Southeast Asia can realize its commercial promise amid geopolitical rivalry
- An AI slowdown that takes some air out of the exuberance could actually extend the boom, Wall Street veteran says
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors